Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
AN2 Therapeutics reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The filing states that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference in other filings except by specific reference. The report is dated August 12, 2025 and is signed by Chief Executive Officer Eric Easom.
AN2 Therapeutics, Inc. (ANTX) filed a Form 4 reporting a routine equity grant to director Kabeer Aziz. On 07/10/2025 Mr. Aziz received 11,875 shares of common stock issued in lieu of cash compensation under the company’s non-employee director compensation policy. Because the award was compensation, the shares were priced at $0.00 and vested immediately.
Following the grant, Mr. Aziz now directly holds 30,552 shares. He also has indirect beneficial ownership—through Adjuvant Global Health Technology Fund, L.P. (1,995,958 shares) and Adjuvant Global Health Technology Fund DE, L.P. (377,542 shares)—bringing total reported influence to roughly 2.404 million shares. However, the filing notes that voting and dispositive power is shared with the funds’ general partners and that beneficial ownership is disclaimed except for pecuniary interest.
No derivative securities, options, sales, or open-market purchases were reported, and no cash was exchanged. The transaction appears purely compensatory and does not signal a deliberate insider buy or sell decision. Investors typically view such awards as neutral unless the size represents a material percentage of total shares outstanding, which the filing does not disclose.